Ferring Pharmaceuticals said it reached an agreement with Apricus Biosciences Inc. to acquire the rights and assets outside of the United States market for Apricus' Vitaros, a topical cream for erectile dysfunction.
"Urology is a key therapeutic area for Ferring," Michel Pettigrew, president of the executive board and chief operating officer of Ferring Pharmaceuticals, said in a press release. “This agreement strengthens our existing portfolio and reinforces Ferring’s commitment to improving the quality of life of patients with a broad range of urological conditions."
Ferring is already Apricus’ existing partner for Vitaros in Latin America and parts of Europe and Asia, in respect to commercialization.
Under the new agreement, Ferring will be responsible for managing all Vitaros-related activities outside of the U.S.